Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.
Jonathan Lee, MD, MSc
Advertisement
Jonathan Lee, MD, MSc, is a chief Hematology/Oncology Fellow at Weill Cornell Medicine.
Articles by Jonathan Lee, MD, MSc
Experts discuss the importance of real-world data in pancreatic cancer treatment, highlighting its impact on patient management and survival outcomes.
Jonathan Lee, MD, MSc, offers his tips for interviewing for a hematology/oncology fellowship.
Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.
Experts discuss evolving treatment strategies for metastatic pancreatic cancer, comparing NALIRIFOX and FOLFIRINOX in first-line therapy decisions.
Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MSc discuss advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS.
The chief oncology/hematology fellow at Weill Cornell Medicine details everything that he wishes he had known entering his first year of fellowship.
Advertisement
Latest Updated Articles
Understanding Your New Role as a Hematology/Oncology FellowPublished: September 3rd 2025 | Updated:
Advances in EGFR-Mutant, HER2-Positive, and Oncogene-Driven NSCLC Highlighted at CFS: With Benjamin P. Levy, MD, and Jonathan W. Lee, MD, MScPublished: November 14th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
5